When GTCB announce their partnership, one of the things I would like to see is that the partner will quickly initiate rATIII trials in aquired indications other than sepsis. GTCB keeps mentioning the myriad uses of rATIII. It would really back up their comments if say a trial begins for coronary heart bypass for example. This would validate GTCB's and keep rATIII and GTCB's eggs from being all in the sepsis basket. I would also like the parner to be responsibile for all the expenses. Is that too much to ask??
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.